---
layout: default
title: Regorafenib
description: "Regorafenib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 8 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 145
evidence_level: L2
indication_count: 8
---

# Regorafenib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>8</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Regorafenibï¼šå¾å¤§è…¸ç›´è…¸ç™Œåˆ°è„‚è‚ªè‚‰ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Regorafenib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Regorafenib æ˜¯ä¸€ç¨®å¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ï¼ˆGISTï¼‰å’Œè‚ç´°èƒç™Œçš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è„‚è‚ªè‚‰ç˜¤ (Liposarcoma)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **2 å€‹è‡¨åºŠè©¦é©—**å’Œ **9 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ã€è‚ç´°èƒç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | liposarcomaã€ovarian myxoid liposarcomaã€clear cell renal carcinomaã€unclassified renal cell carcinomaã€renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusionsã€renal cell carcinoma associated with neuroblastomaã€childhood kidney cell carcinomaã€vulva sarcoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.76% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. liposarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.76%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Regorafenib æ˜¯ä¸€ç¨®å£æœå¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼Œå¯æŠ‘åˆ¶å¤šç¨®åƒèˆ‡è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€è…«ç˜¤å¾®ç’°å¢ƒå’Œè…«ç˜¤å¢æ®–çš„æ¿€é…¶ï¼ŒåŒ…æ‹¬ï¼š
- VEGFR1-3ï¼ˆè¡€ç®¡æ–°ç”Ÿï¼‰
- TIE2ï¼ˆè¡€ç®¡æ–°ç”Ÿï¼‰
- PDGFR-Î²ï¼ˆè…«ç˜¤å¾®ç’°å¢ƒï¼‰
- FGFRï¼ˆçº–ç¶­æ¯ç´°èƒç”Ÿé•·å› å­å—é«”ï¼‰
- KITã€RETã€RAFï¼ˆè…«ç˜¤å¢æ®–ï¼‰

è„‚è‚ªè‚‰ç˜¤æ˜¯ä¸€ç¨®æºè‡ªè„‚è‚ªçµ„ç¹”çš„æƒ¡æ€§è…«ç˜¤ï¼Œå±¬æ–¼è»Ÿçµ„ç¹”è‚‰ç˜¤ã€‚èˆ‡å¤§è…¸ç›´è…¸ç™Œå’Œ GIST é¡ä¼¼ï¼Œè„‚è‚ªè‚‰ç˜¤çš„ç”Ÿé•·å’Œè½‰ç§»ä¹Ÿä¾è³´è¡€ç®¡æ–°ç”Ÿå’Œç‰¹å®šçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚

Regorafenib çš„å¤šæ¨™é¶ç‰¹æ€§ä½¿å…¶åœ¨æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿå’Œè…«ç˜¤å¾®ç’°å¢ƒæ–¹é¢å…·æœ‰æ½›åœ¨å„ªå‹¢ã€‚å·²æœ‰å¤šé …è‡¨åºŠè©¦é©—ï¼ˆåŒ…æ‹¬ SARC024 å’Œ REGOSARCï¼‰æ¢è¨ regorafenib åœ¨è»Ÿçµ„ç¹”è‚‰ç˜¤ä¸­çš„ç™‚æ•ˆã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT02048371](https://clinicaltrials.gov/study/NCT02048371) | Phase 2 | å·²å®Œæˆ | 131 | SARC024ï¼šRegorafenib ç”¨æ–¼è„‚è‚ªè‚‰ç˜¤ã€éª¨è‚‰ç˜¤ã€Ewing è‚‰ç˜¤ç­‰ |
| [NCT01900743](https://clinicaltrials.gov/study/NCT01900743) | Phase 2 | å·²å®Œæˆ | 219 | REGOSARCï¼šRegorafenib vs å®‰æ…°åŠ‘ç”¨æ–¼è»Ÿçµ„ç¹”è‚‰ç˜¤ï¼ŒåŒ…å«è„‚è‚ªè‚‰ç˜¤çµ„ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [27751846](https://pubmed.ncbi.nlm.nih.gov/27751846/) | 2016 | RCT | Lancet Oncol | REGOSARC è©¦é©—ï¼šregorafenib å°è»Ÿçµ„ç¹”è‚‰ç˜¤çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ |
| [32701199](https://pubmed.ncbi.nlm.nih.gov/32701199/) | 2020 | RCT | The Oncologist | SARC024 è„‚è‚ªè‚‰ç˜¤çµ„çµæœï¼šä¸æ”¯æŒ regorafenib å¸¸è¦ç”¨æ–¼è„‚è‚ªè‚‰ç˜¤ |
| [29902612](https://pubmed.ncbi.nlm.nih.gov/29902612/) | 2018 | RCT | Eur J Cancer | REGOSARC æ›´æ–°åˆ†æï¼šregorafenib å°éè„‚è‚ªè‚‰ç˜¤æœ‰æ•ˆï¼Œè„‚è‚ªè‚‰ç˜¤æ•ˆæœä¸ä½³ |
| [29931504](https://pubmed.ncbi.nlm.nih.gov/29931504/) | 2018 | Review | Target Oncol | Regorafenib åœ¨è‚‰ç˜¤æ²»ç™‚ä¸­çš„è§’è‰² |
| [25884155](https://pubmed.ncbi.nlm.nih.gov/25884155/) | 2015 | Protocol | BMC Cancer | REGOSARC è©¦é©—æ–¹æ¡ˆ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. ovarian myxoid liposarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.68%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. clear cell renal carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.47%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.47%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. unclassified renal cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.24%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.24%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. renal cell carcinoma associated with neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.24%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. childhood kidney cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.07%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. vulva sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.06%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | ç™Œç‘æ ¼è†œè¡£éŒ 40æ¯«å…‹ | è†œè¡£éŒ  | å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ã€è‚ç´°èƒç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æ¨™é¶è—¥ç‰©ï¼ˆå¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä½è‡³ä¸­åº¦ï¼ˆå¯èƒ½å‡ºç¾è¡€å°æ¿æ¸›å°‘ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCã€è‚åŠŸèƒ½ï¼ˆALT/AST/Bilirubinï¼‰ã€è¡€å£“ã€çš®è†šåæ‡‰ |
| è™•ç½®é˜²è­· | å£æœè—¥ç‰©ï¼Œéµå¾ªä¸€èˆ¬è—¥ç‰©è™•ç½®è¦ç¯„å³å¯ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è‚æ¯’æ€§ï¼šå¯èƒ½å‡ºç¾åš´é‡è‚æå‚·ï¼Œéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- æ‰‹è¶³çš®è†šåæ‡‰ï¼ˆHFSRï¼‰ï¼šå¸¸è¦‹ä¸è‰¯åæ‡‰
- é«˜è¡€å£“ï¼šéœ€ç›£æ¸¬è¡€å£“

**ç¦å¿Œç—‡ï¼š**
è«‹åƒè€ƒåŸå» ä»¿å–®

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šDepending on the amount of fat, food may enhance the oral bioavailability of both regorafenib and its active metabolites, M-2 and M-5.
- å»ºè­°ï¼šTo ensure optimal oral absorption, regorafenib should be administered with a low-fat breakfast that contains less than 30% fat.  Examples of a low-fat breakfast include:  2 slices of white toast with ...

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šDepending on the amount of fat, food may enhance the oral bioavailability of both regorafenib and its active metabolites, M-2 and M-5.
- å»ºè­°ï¼šTo ensure optimal oral absorption, regorafenib should be administered with a low-fat breakfast that contains less than 30% fat.  Examples of a low-fat breakfast include:  2 slices of white toast with ...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½æ¨™é¶è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Lung Diseases** ğŸŸ¡ Moderate
- The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recomme...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ SARC024 å’Œ REGOSARC è©¦é©—å·²æ¢è¨ regorafenib ç”¨æ–¼è„‚è‚ªè‚‰ç˜¤ï¼Œä½†çµæœé¡¯ç¤ºåœ¨è„‚è‚ªè‚‰ç˜¤äºçµ„ä¸­ç™‚æ•ˆæœ‰é™ã€‚é€™èˆ‡å…¶ä»–è»Ÿçµ„ç¹”è‚‰ç˜¤äºå‹ï¼ˆå¦‚å¹³æ»‘è‚Œè‚‰ç˜¤ã€æ»‘è†œè‚‰ç˜¤ï¼‰çš„æ­£é¢çµæœå½¢æˆå°æ¯”ã€‚ç„¶è€Œï¼Œç”±æ–¼ä»æœ‰éƒ¨åˆ†æ‚£è€…å¯èƒ½ç²ç›Šï¼Œä¸”ç¼ºä¹å…¶ä»–æœ‰æ•ˆæ²»ç™‚é¸æ“‡ï¼Œåœ¨å……åˆ†çŸ¥æƒ…åŒæ„ä¸‹å¯è€ƒæ…®ä½¿ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ ¹æ“š SARC024 å’Œ REGOSARC è©¦é©—çµæœï¼Œè¬¹æ…è©•ä¼°æ‚£è€…æ˜¯å¦é©åˆ
- å¯†åˆ‡ç›£æ¸¬è‚åŠŸèƒ½å’Œçš®è†šåæ‡‰
- æ¢ç´¢èˆ‡å…¶ä»–ç™‚æ³•ï¼ˆå¦‚å…ç–«æ²»ç™‚ï¼‰çš„çµ„åˆæ–¹æ¡ˆ
- è€ƒæ…®ç”Ÿç‰©æ¨™è¨˜ç‰©ä»¥ç¯©é¸å¯èƒ½ç²ç›Šçš„æ‚£è€…äºç¾¤


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Regorafenibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/regorafenib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_regorafenib,
  title = {Regorafenibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/regorafenib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
